3d ā¢ General discussion
š Food for Thought: The Survodutide Hedge Against Big P
Everyone's losing their minds over Eli Lilly doomsday scenarios - generic tirz flooding the market, potential crackdowns, the research peptide space collapsing, etc.
Here's something interesting: Eli Lilly doesn't own survodutide.
Boehringer Ingelheim does.
So even if every single worst-case scenario about sema, tirz, and reta comes true... survodutide operates in a completely different corporate universe with different timelines, different patents, different legal strategies.
Different company = different dynamics = different risks.
Just something to keep in mind when everyone's panicking about one pharmaceutical giant. The peptide space isn't a monolith, and not every compound is tied to the same corporate fate.
This isn't investment or medical advice - just pointing out that the industry has more moving pieces than people realize.
What are your thoughts? Are people too focused on Eli Lilly and missing the bigger picture?
22
29 comments
š Food for Thought: The Survodutide Hedge Against Big P
powered by
skool.com/peptide-price-9771
Premier peptide education hub. FREE courses on research peptides & GLP-1s. US supplier intel, safety protocols & expert community support. š§¬š
Suggested communities
Powered by